No Data
No Data
Spectral Medical Brief: Says Net Proceeds From Offering Expected to Be Primarily Used by the Co on Its Phase III Registration Trial (Tigris) for Its PMX Treatment for Endotoxemic Septic Shock and for General Corporate and Working Capital Purposes
Spectral Medical Inc. Announces Change to Auditor
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
Shareholders May Be More Conservative With Spectral Medical Inc.'s (TSE:EDT) CEO Compensation For Now
Spectral Medical Q1 Loss Widens, Says Tigris Trial Enrollment Reaches 106 Patients
Spectral Medical Brief: Loss for the Three-months Ended March 31, 2024 Was $4,160,000 ($0.01 per Share)